Is Adding HCV Screening to the Antenatal National Screening Program in Amsterdam, The Netherlands, Cost-Effective?

• Anouk T. Urbanus ,

  Contributed equally to this work with: Anouk T. Urbanus, Marjolijn van Keep

  * E-mail: aurbanus@ggd.amsterdam.nl

  Affiliations Cluster of Infectious Diseases, Public Health Service, Amsterdam, The Netherlands, Center for Infection and Immunology Amsterdam (CINIMA), Academic Medical Centre (University of Amsterdam), Amsterdam, The Netherlands

  ⨯
• Marjolijn van Keep ,

  Contributed equally to this work with: Anouk T. Urbanus, Marjolijn van Keep

  Affiliation Department of Pharmacy, Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), University of Groningen, Groningen, The Netherlands

  ⨯
• Amy A. Matser,

  Affiliations Cluster of Infectious Diseases, Public Health Service, Amsterdam, The Netherlands, Julius Center for Health Science and Primary Health Care, University Medical Center Utrecht, The Netherlands

  ⨯
• Mark H. Rozenbaum,

  Affiliation Department of Pharmacy, Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), University of Groningen, Groningen, The Netherlands

  ⨯
• Christine J. Weegink,

  Affiliation Department of Gastroenterology and Hepatology (AMC Liver Centre), Academic Medical Centre (University of Amsterdam), Amsterdam, The Netherlands

  ⨯
• Anneke van den Hoek,

  Affiliations Cluster of Infectious Diseases, Public Health Service, Amsterdam, The Netherlands, Center for Infection and Immunology Amsterdam (CINIMA), Academic Medical Centre (University of Amsterdam), Amsterdam, The Netherlands

  ⨯
• Maria Prins,

  Affiliations Cluster of Infectious Diseases, Public Health Service, Amsterdam, The Netherlands, Center for Infection and Immunology Amsterdam (CINIMA), Academic Medical Centre (University of Amsterdam), Amsterdam, The Netherlands

  ⨯
• Maarten J. Postma

  Affiliation Department of Pharmacy, Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), University of Groningen, Groningen, The Netherlands

  ⨯